All In MedTech

Device Trial Radar · NCT05412966

Feasibility Study of Novel Prescription Digital Therapeutic Supporting Unobserved Buprenorphine Initiation & Adherence

A Feasibility Study of PEAR-002b, a Novel Prescription Digital Therapeutic to Support Unobserved Buprenorphine Initiation and Adherence in Opioid Use Disorder Outpatients

Last checked: Nov 20, 2026Latest source record: Jan 9, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

7

Actual

Start

Nov 4, 2022

Primary completion

Nov 23, 2022

Study completion Dec 16, 2022

Sponsor

Lead sponsor
Pear Therapeutics, Inc.Not on our public-company list
Sponsor type
Industry
Collaborators
Kaiser Foundation Research Institute; Whitman-Walker Institute, Inc.; National Institute on Drug Abuse (NIDA); Hassman Research Institute, LLC
First posted
Jun 9, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess feasibility of an at-home digital therapy designed to support buprenorphine initiation and adherence.

Conditions

  • Opioid Use Disorder

Interventions

  • PEAR-002BDevice

    PEAR-002B is a novel prescription digital therapeutic to support unobserved buprenorphine initiation and adherence in Opioid Use Disorder

  • reSET-ODevice

    reSET-O is an FDA-authorized mobile application treatment for opioid use disorder.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PEAR-002B User Satisfaction SurveysTime frame: Week 1
  2. PEAR-002B Qualitative User Experience InterviewsTime frame: Week 1
  3. Buprenorphine Initiation SuccessTime frame: Week 1

1 more outcomes with a free account

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hassman Research Institute, LLC

    Berlin, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.